Myriad Genetics (MYGN) Non-Current Assets (2010 - 2026)

Myriad Genetics (MYGN) has reported Non-Current Assets for 17 consecutive years, with $360.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets fell 49.8% year-over-year to $360.9 million; the TTM figure through Mar 2026 stood at $1.5 billion (down 50.13% YoY), while the FY2025 annual figure was $374.0 million, down 48.74% from the prior year.
• Non-Current Assets declined to $360.9 million in Q1 2026 per MYGN's latest filing, from $374.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $924.1 million in Q4 2022 and bottomed at $360.9 million in Q1 2026.
• Historically, Non-Current Assets has averaged $725.5 million across 5 years, with a median of $820.2 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets rose 10.55% — and 2025, when it sank 51.36%.
• Myriad Genetics' Non-Current Assets stood at $924.1 million in 2022, then decreased by 9.87% to $832.9 million in 2023, then retreated by 12.4% to $729.6 million in 2024, then plunged by 48.74% to $374.0 million in 2025, then slipped by 3.5% to $360.9 million in 2026.
• Business Quant data shows MYGN's Non-Current Assets at $360.9 million in Q1 2026, $374.0 million in Q4 2025, and $383.3 million in Q3 2025.